

ORGANIGRAM SECURES \$6,350,000 IN A NON-BROKERED PRIVATE PLACEMENT TO POSITION THE COMPANY FOR NATIONAL LEGALIZATION

Moncton, N.B. November 5, 2015 – OrganiGram Holdings Inc. (TSX-V: OGI) (OTC US:OGRMF) (“**OrganiGram**” or the “**Company**”) is pleased to announce that, subject to TSX Venture Exchange approval, the Company has secured a non-brokered private placement offering for net proceeds of \$6,350,000 (the "Offering").

The Company will issue an aggregate of 3,298,077 units ("Units") at a price of \$1.04 per Unit (the "Offering Price") for net proceeds of \$3,430,000. Each Unit consists of one common share of the Company (a "Common Share"), and one-half of a share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will be exercisable into one additional Common Share (a "Warrant Share") of the Company at \$1.40 per Warrant Share for a period of eighteen (18) months from closing of the Offering. The Company intends to use the proceeds from the Offering for accelerated facility expansion and general working capital purposes.

In addition, the Company has secured convertible debentures in the aggregate amount of \$2,920,000 which carry an interest rate of 6.75% and which mature on December 31, 2018. The debentures may be converted by the debenture holder at a ratio of 714.286 shares per \$1,000 of the principal amount converted.

“OrganiGram is pleased to have secured this financing. Management appreciates the confidence demonstrated by its Board of Directors, as all members of the Board participated in this financing round. With the newly elected Federal Government’s platform position to legalize recreational marijuana, the Company looks forward to allocating this capital effectively to expand the facility, enhance working capital and continue marketing initiatives.” said Roger Rogers, President & CFO.

It is anticipated that related parties of the Company will acquire shares and warrants under the private placement. Such participation would be considered to be “related party transactions” within the meaning of the TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 (“MI 61-101”). The company intends to rely on the exemptions from the formal valuation and minority approval requirements of MI 61-101 in respect of related party participation as at the time the transaction is agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves interested parties, exceeds 25 per cent of the Company’s market capitalization.

Completion of this placement is subject to the approval of the TSX Venture Exchange.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the *Marihuana for Medical Purposes Regulations*.

On behalf of the board of directors,

Denis Arsenault

Director and CEO
OrganiGram Holdings Inc.

For further information please visit www.organiagram.ca or contact:

Brett Allan
Director of Investor Relations
OrganiGram Holdings Inc.
(647) 229-6627

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of operations -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.